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INTRODUCTION
Ovarian cancer is the sixth most common
malignancy in women after uterine cervical, breast,
colorectal, skin, and lymphoma cancer. Up to 70%
of ovarian cancer is diagnosed at advanced stage
that have spread into upper abdominal cavity
(stage III) or wider (stage IV) with 5 years survival
rate at 15-20%, whereas survival rate at stage I
and stage II are predicted at lower rate of 90% and
70%.1,2
Patients are mostly diagnosed at more advanced
stage as early diagnostic tool is still not available.
One of the mostly used tumor markers is cancer
antigen (CA) 125. To date, CA 125 is the best tumor
marker available in diagnosing and monitoring
ovarian cancer patients. However, CA 125 increases
only in 80% of patients in late stages and 50% of
patients in early stages. About 20% of patients of
early stages ovarian cancer have normal CA 125
values.2
Abstract
Objective: To assess the diagnostic value of Risk of Ovarian
Malignancy Algorithm (ROMA) in predicting ovarian
malignancy.
Methods: Diagnostic test was performed at dr. Mohammad Hoesin
Hospital Palembang during June 2016 to November 2016. Data were
analized with SPSS version 21.0 and Med-calc statistic.
Results: A total of 57 subjects were recruited in this study.
Subjects were divided into two groups: the premenopausal and
postmenopausal group. Analysis with ROC curve was performed,
the ROMA optimal cut-off of ROMA was 23.7% and 48.15% in the
premenopausal and the post-menopausal group, respectively.
With the optimal cut-off, the sensitivity was 79.41% and
specivicity was 75%, positive predictive value wa 73.07% and
negative predictive value 83.77% with accuracy 76.92% in
diagnosing ovarian malignancy. Compared to RMI-3, the sen-
sitivity was 65.5% and specivicity was 85.7% with accuracy
75.44%.
Conclusion: ROMA is not a reliable diagnostic tools of ovarian
malignancy.
[Indones J Obstet Gynecol 2017; 5-4: 236-240]
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Abstrak
Tujuan: Menilai nilai diagnostik Risk of Ovarian Malignancy
Algorithm (ROMA) dalam memprediksi keganasan ovarium.
Metode: Penelitian uji diagnostik dilakukan di RSUP dr. Mohammad
Hoesin Palembang selama periode Juni 2016 - November 2016, seba-nyak 61 wanita dengan tumor ovarium dimasukkan sebagai subjek
penelitian, 4 pasien dieksklusi karena perbedaan diagnosis saat
intraoperatif. Data kemudian dianalisis dengan menggunakansoftware SPSS versi 21.0 dan Med-calc statistic.
Hasil: Dari 57 pasien yang memenuhi kriteria inklusi dan eksklusi.
Pasien dibagi menjadi dua kelompok yaitu kelompok premenopause
dan menopause. Dilakukan analisis dengan kurva ROC didapatkancut-off optimal ROMA pada penelitian ini yaitu 23,7% untuk
kelompok premenopause dan 48,15% untuk kelompok menopause.
Dilakukan uji diagnostik, didapatkan sensitivitas 79,41% danspesifisitas 75%, nilai duga positif adalah 73,07% dan nilai duga
negatif 83,77% dengan nilai akurasi 76,92% dalam mendiagnosakeganasan ovarium. Dibandingkan dengan RMI-3, didapatkan nilai
sensitivitas 65,5% dan spesifisitas 85,7% dengan nilai akurasi
75,44%.
Kesimpulan: Pemeriksaan ROMA bukan merupakan uji diagnostik
keganasan ovarium yang akurat.
[Maj Obstet Ginekol Indones 2017; 5-4: 236-240]
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Several biomarkers have been tested lately as
alternatives or additional markers to differentiate
benign from malignant tumor. Human Epididymis4
(HE4) is a promising biomarker to be used. HE4, a
glycoprotein, is over expressed in ovarian cancer
particularly.3
Moore et al .  designed Risk of Ovarian
Malignancy Algorithm (ROMA), using blood test
algorithm, as a simpler biomarker compared to
RMI (risk malignancy index) that requires ultra-
sonography. They reported significant increase in
sensitivity and specificity when HE4 and CA125 are
used in combination. In a further study comparing
ROMA and RMI, Moore et al. reported higher
sensitivity and specificity in ROMA.4,5
Karlsen et al. reported a high sensitivity (94.8%)
and specificity (75%) results of ROMA in
diagnosing ovarian cancer.6 Molina et al. also
reported a better sensitivity (90.1%) and
specificity (87.1%) results of ROMA compare to
CA125, but it is might further improved if it is used
with normal HE4 and abnormal CA125.7
RMI is one of the most frequent used
methods  in  ident i fy ing  malignancy and
considered as a simple method which uses
menopause status, ultrasound and CA125 level.
Jacobs et al. obtained sensitivity of 85.4% and
specificity of 96.9% using cut-off 200. However,
Andriata et al. obtained a different results in
using the same RMI method: sensitivity of 8.4%
and specificity of 76.9%.8
Anton et al. from Brazil did the same comparison
of ROMA and RMI and no significant difference was
found between diagnostic values of ROMA and
RMI.9 Normal value of biomarkers such as CA125
and HE4 varies in different population. Pauler et al.
reported a difference in normal value of CA125 in
Caucasian and Asian. Several studies have been
done to find normal values of these markers in
different populations. This difference in normal
values could alter the outcome of ROMA. Therefore,
Karen et al. proposed different cut-off values for
different population to accommodate this variation
of normal values in different population.10 This
study is aimed to assess the diagnostic value of
ROMA in predicting ovarian malignancy.
METHODS
Diagnostic tests and cross sectional design were
used on 61 women with ovarian cancer and were
planned for operative procedure. This research
was conducted at Obstetrics and Gynecologic
Department of Dr. Mohammad Hoesin Palembang
Hospital from June 2016 to November 2016.
Inclusion criteria were women diagnosed with
ovarian cancer who are being planned to undergo
surgical procedures. The diagnosis of ovarian
cancer was based on anamnesis, physical exami-
nation, and ultrasonography. Exclusion criteria
were women diagnosed with non-gynecologic
malignancies, pregnancy, kidney failure or intra-
operative mass of non-ovarian origin.
Gestational age, parity, education level, occupa-
tion, smoking, contraception, physical examination,
ultrasonography, post-operative CA125 and HE4 of
the subjects were recorded. CA125 and HE4 tests
were carried out by using architect reagent and
histopathology results were masked. ROMA score
was calculated by software downloaded from
http://romatools.he4test.com/.
Data were analyzed with SPSS 21.0. The cut-off
point value of ROMA was determined by
Receiving Operating Characteristic (ROC) curve.
Sensitivity, specificity, positive predictive value,
negative predictive value, likelihood ratio were
calculated by med-calc statistic.
RESULTS
Demographic and the tumor characteristics of the
subjects are presented in Table 1. Mean age of
samples was 40.51 years old with majority of the
patients were from pre-menopause group (56.1%)
and higher tendency found in multipara (43.9%).
Table 1. Demographic and Tumor Characteristics of the
Subjects
Characteristic
Frequency
N %
Age, meanSD 40.5116.32
(6-64)
Pre-menopause 32 56.1
Menopause 25 43.9
Parity
Not Married 11 19.3
Primipara 21 36.8
Multipara 25 43.9
Pathology
Malignant 24 42.2
Borderline 5 8.7
Benign 28 49
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Type
Epithelial 45 78.9
Non-Epithelial 12 21.1
Total 57 100
In this study, alternative cut-off point of ROMA
was determined by using ROC curve. Patients were
divided into two groups, consisting of the pre-
menopausal and post-menopausal group. For the
post-menopausal the group, the optimal cut-off
point of ROMA was obtained at 58.15% with sen-
sitivity of 47.15%, specificity of 71.4%, positive
predictive value of 86.6% and negative predictive
value of 50% as shown in Figure 1 below.
In the pre-menopausal group, the optimal cut-off
point of ROMA was obtained at 23.7% with
sensitivity of 72.72% and specificity of 76.19%,
positive predictive value of 61.54% and negative
predictive value of 84.21% (Figure 2).
Diagnostic test was done with alternative cut-off
with borderline histopathology was included as
malignant group. Results obtained were then
compared to those of standard cut-off. As RMI-3 is
frequently used to predict malignant to benign
ovarian tumor, we also compared ROMA to RMI-3
with standard cut-off > 200 for prediction of
malignancy (Table 2).
Table 2. Diagnostic Value of RMI-3 vs ROMA Alternativevs ROMA Standard with Borderline Included
Benign vs
Malignant +
Borderline
ROMA
alternative
ROMA
standard
RMI­3
Sensitivity, % 65.5 82.7 65.5
Specificity, % 85.7 64.2 85.7
PPV, % 82.6 70.5 82.6
NPV, % 70.5 78.2 70.5
Accuracy, % 75.44 73.68 75.44
If samples with borderline histopathology were
not included as malignant group, better diagnostic
results were obtained. RMI-3 have better sensi-
tivity and specificity compared to ROMA results
without borderline histopathology included as
shown in Table 3.
Table 3. Diagnostic Value of RMI-3 vs ROMA Alternative
vs ROMA Standard with Borderline Excluded
Benign vs
Malignant
ROMA
alternative
ROMA
standard
RMI­3
Sensitivity, % 79.41 91.67 70.83
Specificity, % 75 64.2 85.7
PPV, % 73.07 68.75 90.47
NPV, % 83.77 90.00 77.41
Accuracy, % 76.92 76.92 78.84
DISCUSSION
Almost 70% of ovarian cancer were diagnosed at
later stage with 5-year survival rate at about
15-20%, whereas survival rate at stage I and stage
II were predicted at 90% and 70%.
ROMA, a test using combination of CA125, HE4,
and menopause status, is an effective diagnostic
tool to diagnose ovarian cancer. The effectiveness
of ROMA as pre-operative diagnosis tool in patients
with pelvic mass have been proven by several
Figure  1. ROC curve of ROMA of the post-menopausal
group
Figure  2. ROC curve of ROMA of the pre-menopausal
group
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studies though there are still doubts of its
superiority due to variations in cut-off values to
diagnose malignancy.
Gorp et al. and Anton et al. have shown different
cut-off values for different populations resulting in
different diagnostic values. Hence, this study is
aimed to find an alternative cut-off value to be
compared with standard cut-off value and RMI
which often used as a diagnostic tool.7,8,11,12
In this research, by using ROC analysis,
alternative cut-off values were obtained at 23.7%
for pre-menopause and 48.15% for menopause
(72.41% sensitivity, 75% specificity, 73.68%
accuracy) when patients with borderline histo-
pathology were included as malignant group.
Better results were obtained (79.41% sensitivity,
75% specificity, 76.68% accuracy) when patients
with borderline histopathology were not included
in malignant group. Using standard cut-off, ROMA
has better sensitivity (82.7% including borderline;
91.67% if borderline was excluded).
RMI-3 diagnostic value was also improved when
borderline histopathology was not included in the
malignant group: 70.83% for sensitivity; 85.7% for
specificity; and 78.84% for accuracy.
In this study, the median age was 40.51 years
old which is close to Winarto’s median age of 41
years old, and the proportion of the post-meno-
pausal women was 37.8%. There were also differ-
ences in the dominant type of tumor. Mucinous
type of ovarian carcinoma was more dominant
(41%) in this research compared to Moore’s,
Molina’s and Karlsen’s in which serous type of
ovarian cancer was more dominant (>75%).4,5,9,10
Sensitivity and specificity of ROMA in this study
are lower compared to Moore’s, Van Gorp’s and
Chudezka’s. These differences may be attributed to
different demographic data in which past meno-
pausal patients were more dominant in Moore’s
(53.3%), Van Gorp’s (53.2%) and Chudezka
(61.9%) while in this study pre-menopausal group
was dominant (56.1%).4,11,12 In this study, when
diagnostic test was done for post-menopausal
group, ROMA with standard cut-off gives better
sensitivity and accuracy (88.9% and 80%). This
result showed that ROMA probably gave a better
performance when used in the menopausal group.
RMI method was first designed by Jacobs et al.
by using ultrasonography combined with CA125
value. In this study, no difference was found
between RMI and ROMA. However, the accuracy of
RMI3 was the highest, which is amounted to
78.85% in subjects with borderline histopathology
not included as malignancy.
The limitations of this study were smaller
samples compared to previous studies and no FSH
measurement done to differentiate post-meno-
pausal and pre-menopausal subjects.
CONCLUSION
ROMA is not a reliable diagnostic tool. Compared
to RMI3, ROMA has lower sensitivity. Overall, RMI3
has a better diagnostic value compare to ROMA.
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